Summary
Since pregnancy and the time thereafter is a precarious period for women with recurrent affective disorders and their offspring, it is important to determine the risk of various treatments for such disorders. This review assesses the risk to the fetus, the perinatal risks for mother and infant, the risks associated with treatment during the puerperium and breastfeeding, and the risks to the later development of the child.
This review considers treatment with lithium, tricyclic antidepressants (TCAs), selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, other antidepressants, and the anticonvulsants carbamazepine and valproic acid (sodium Valproate).
According to available evidence, use of lithium, TCAs and SSRIs is justified during and after pregnancy if treatment is required; no prophylactic treatment has a lower risk: benefit ratio. The review provides guidelines for the use of these drugs.
References
Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 36: 349–52
Schou M, Juel-Nielsen N, Strömgren E, et al. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250–60
Baastrup PC, Schou M. Lithium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162–72
Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; II: 326–30
Schou M. The ’scandinavian Register of Lithium Babies’. Acta Psychiatr Scand 1969; 207 Suppl.: 97
Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy. I, Report form the Register of Lithium Babies. BMJ 1973; 2: 135–6
Weinstein MR, Goldfield MD. Pharmacology: lithium teratology. In: Gershon S, Shopsin B, editors. Lithium: its role in psychiatric research and treatment. New York: Plenum, 1973: 147–66
Schou M. Lithium treatment during pregnancy, delivery, and lactation: an update. J Clin Psychiatry 1990; 51: 410–3
Källen B, Tandberg A. Lithium and pregnancy: a cohort study on manic-depressive women. Acta Psychiatr Scand 1983; 68: 134–9
Cunniff CM, Sahn DJ, Reed KL, et al. Pregnancy outcome in women treated with lithium [abstract]. Teratology 1989; 39:447
Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530–3
Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146–50
Zalzstein E, Koren G, Einarson T, et al. A case-control study on the association between first trimester exposure to lithium and Ebstein’s anomaly. Am J Cardiol 1990; 65: 817–8
Edmonds LD, Oakley GP. Ebstein’s anomaly and maternal lithium exposure during pregnancy. Teratology 1990; 41: 551–2
Sipek A. Lithium and Ebstein’s anomaly. Cor Vasa 1989; 31: 149–56
Källen SJB. Lithium therapy and congenital malformations. In: Schrauzer GN, Klippel KF, editors. Lithium in biology and medicine: new applications and developments. Weinheim: New York, 1991: 121–30
Thomsen K, Schou M. Renal lithium excretion in man. Am J Physiol 1968; 215: 823–7
Schou M, Amdisen A, Steenstrup OR. Lithium and pregnancy. II: hazards to women given lithium during pregnancy and delivery. BMJ 1973; 2: 137–8
Wilbanks GD, Bressler B, Peete CH, et al. Toxic effects of lithium carbonate in a mother and newborn infant. JAMA 1970; 213: 865–7
Vacaflor L, Lehmann HE, Ban TA. Side effects and teratogenicity of lithium carbonate treatment. J Clin Pharmacol 1970; 10: 387–9
Nishiwaki T, Tanaka K, Sekiya S. Acute lithium intoxication in pregnancy. Int J Gynecol Obstet 1996; 52: 191–2
Tunnesen WW, Hertz CG. Toxic effects of lithium in newborn infants: a commentary. J Pediatrics 1972; 81: 804–7
Stothers K, Wilson DW, Royston N. Lithium toxicity in the newborn. BMJ 1973; 3: 233–4
Stevens D, Burman D, Midwinter A. Transplacental lithium poisoning. Lancet 1974; II: 595
Nars P, Girard J. Lithium carbonate intake during pregnancy leading to large goiter in a premature infant. Am J Dis Child 1977; 131: 924–5
Mizrahi EM, Hobbs JF, Goldsmith DI. Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Pediatrics 1979; 94: 493–5
Arnon RG, Marin-Garcia J, Peeden JN. Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant. Am J Dis Childhood 1981; 135: 941–3
Filtenborg JA. Persistent pulmonary hypertension after lithium intoxication in the newborn. Eur J Pediatr 1982; 138: 321–3
Morrell P, Sutherland GR, Buamah PK, et al. Lithium toxicity in a neonate. Arch Dis Child 1983; 58: 539–41
Wilson N, Forfar JC, Godman MJ. Atrial flutter in the newborn resulting from maternal lithium ingestion. Arch Dis Child 1983; 58: 538–49
Krause S, Ebbesen F, Lange AP. Polyhydramnios with maternal lithium treatment. Obstet Gynecol 1990; 75: 504–6
Ang MS, Thorp JA, Parisi VM. Maternal lithium therapy and polyhydramnios. Obstet Gynecol 1990; 76: 517–9
Kastrup M, Lier L, Rafaelsen OJ. Psychiatric illness in relation to pregnancy and childbirth. I. Methodological considerations. Nord Psykiatr Tidsskr 1989; 43: 531–4
Lier L, Kastrup M, Rafaelsen OJ. Psychiatric illness in relation to pregnancy and childbirth. II. Diagnostic profiles, psychosocial and perinatal aspects. Nord Psykiatr Tidsskr 1989; 43: 535–42
Austin MV. Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry 1992; 161: 692–4
Cohen LS, Sichel DA, Robertson LM, et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995; 152: 1641–5
Schou M, Amdisen A. Lithium and pregnancy. III: lithium ingestion by children breast-fed by women on lithium treatment. BMJ 1973; 2: 138
Schou M. Lithium treatment of manic-depressive illness: a practical guide. 4th rev ed. Basel: Karger, 1989
Skausig OB, Schou M. Diegivning under lithiumbehandling. Ugeskr Læg 1977; 139: 400–1
Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153: 1132–7
Schou M. Lithium treatment of manic-depressive illness: a practical guide. 5th rev ed. Basel: Karger, 1993
Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54: 193–7
Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36: 555–9
Akiskal HS, Mallya G. Criteria for the ’soft’ bipolar spectrum: treatment implications. Psychopharmacol Bull 1987; 23: 68–73
Altschuler LL, Cohen L, Szuba MP, et al. Pharmacological management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592–606
Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246–8
McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. Reprod Toxicol 1996; 10: 285–94
Chambers CD, Johnson KA, Dick LM, et al. Birth outcome in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–5
Robert E. Treating depression in pregnancy. N Engl J Med 1996; 335: 1056–8
Cohen LS, Rosenbaum JF. Birth outcome in pregnant women taking fluoxetine [letter]. N Engl J Med 1997; 336: 872
Goldstein DJ, Sundell KL, Corbin LA. Birth outcomes in pregnant women taking fluoxetine [letter]. N Engl J Med 1997; 336: 872–3
Jones KL, Johnson KA, Chambers CD. Birth outcomes in pregnant women taking fluoxetine [letter]. N Engl J Med 1997; 336: 873
Webster PAC. Withdrawal symptoms in neonates associated with maternal antidepressants therapy [letter]. Lancet 1973; II: 3189
Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy [letter]. Lancet 1973; II: 680
Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ 1982; 284: 1837–8
Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in the neonate. Pediatrics 1993; 92: 721–2
Baum AL, Misri S. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harvard Rev Psychiatry 1996; 4: 117–25
Lidén K, Eilström KG. Obervandum om antidepressiva under graviditet: Även låga doser kan påverka barnet. Läkartidn 1997; 94: 2086–91
Wisner KL, Wheeler SB. Prevention of recurrent Postpartum major depression. Hosp Commun Psychiatry 1994; 45: 1191–6
Altschuler LL, Burt VK, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995; 56: 243–5
Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996; 36: 42–7
Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153: 1132–7
Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43: 225–37
Mammen OK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58: 100–3
Jensen PN, Olesen OV, Bertelsen A, et al. Citalopram and desmethylcitalopram in breast milk and in serum of mother and infant. Ther Drug Monit 1997; 18: 236–9
Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997: 336: 258–62
Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989: 320: 1661–6
Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674–7
Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75: 517–20
Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; II: 937
Bjerkedal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida [letter]. Lancet 1982; II: 1096
Lindhout D, Meinardi H. Spina bifida and in-utero exposure to valproic acid. Lancet 1984; II: 396
DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal Valproate syndrome. Am Med J Genet 1984; 19: 473–81
Ardinger HH, Atkin JF, Blackston D, et al. Verification of the fetal Valproate syndrome phenotype. Am J Med Genet 1988; 29: 171–85
Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to Valproate in utero. Arch Dis Child 1993; 69: 288–91
Battino D, Binelli S, Caccamo ML, et al. Malformations in off-spring of 305 epileptic women: a prospective study. Acta Neurol Scand 1992; 85: 204–7
Niebyl JR, Blake DA, Freeman JM, et al. Carbamazepine levels in pregnancy and lactation. Obstet Gynecol 1979; 53: 139–40
Abrams R. Electroconvulsive therapy. 2nd ed. New York: Oxford University Press, 1992: 103–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schou, M. Treating Recurrent Affective Disorders During and After Pregnancy. Drug-Safety 18, 143–152 (1998). https://doi.org/10.2165/00002018-199818020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199818020-00006